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Available online 5 May 2016Dopamine receptors are G protein-coupled receptors involved in regulation of cognition, learning, movement
and endocrine signaling. The action of G protein-coupled receptors is highly regulated by multifunctional pro-
teins, such as β-arrestins which can control receptor desensitization, ubiquitination and signaling. Previously,
we have reported that β-arrestin 2 interacts with KLHL12, a BTB-Kelch protein which functions as an adaptor
in a Cullin3-based E3 ligase complex and promotes ubiquitination of the dopamine D4 receptor.
Here, we have investigated the molecular basis of the interaction between KLHL12 and β-arrestins and
questioned its functional relevance. Our data demonstrate that β-arrestin 1 and β-arrestin 2 bind constitutively
to the most common dopamine D4 receptor polymorphic variants and to KLHL12 and that all three proteins can
interact within a single macromolecular complex. Surprisingly, stimulation of the receptor has no influence on
the association between these proteins or their cellular distribution.
We found that Cullin3 also interacts with both β-arrestins but has no influence on their ubiquitination. Knockout
of one of the two β-arrestins hampers neither interaction between the dopamine D4 receptor and KLHL12, nor
ubiquitination of the receptor.
Finally, our results indicate that p44/42 MAPK phosphorylation, the signaling pathway which is often regulated
by β-arrestins is not influenced by KLHL12, but seems to be exclusivelymediated by Gαi protein upon dopamine
D4 receptor stimulation.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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1.1. Dopamine D4 receptor
Dopamine receptors (DR) belong to the superfamily of G protein-
coupled receptors (GPCR), the largest family of membrane receptors
and the most common drug targets. Dopaminergic signaling controls
many basic processes such as movement, cognition, learning, reward
and endocrine regulation. Aberrant DR signaling has been implicated
in several neurological and psychiatric disorders including schizophre-
nia, Parkinson's disease, Huntington's disease and attention deficit hy-
peractivity disorder (ADHD). Five different dopamine receptors have
been identified which are divided into two subfamilies: the D1-like do-
pamine receptors (D1R and D5R), which signal through Gαs proteins
and the D2-like dopamine receptors (D2R, D3R, and D4R), which signal
through Gαi/o proteins [1–3].
The dopamine D4 receptor (D4R) has gained increasing interest due
to its high affinity for the atypical antipsychotic clozapine, and its poten-
tial in antipsychotic medication [4]. Moreover, this receptor possesses a
remarkable VNTR (variable number of tandem repeats) polymorphism
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peated two to eleven times [4,5]. The precise role of this polymorphism
is not clear, but the seven repeat allele (D4.7R), which has been subject
to positive selection during recent evolution, is associatedwith a predis-
position to develop ADHD [6].
1.2. Importance of β-arrestins in GPCR regulation
GPCR function is highly regulated in multiple ways by β-arrestin
proteins. There are fourmembers of the arrestin family: arrestin 1 (visu-
al arrestin), arrestin 2 (β-arrestin 1), arrestin 3 (β-arrestin 2) and
arrestin 4 (cone arrestin). The visual and cone arrestin are localized to
retina rods and cones and interact mainly with rhodopsin, in contrast,
to the two β-arrestin isoforms which are ubiquitously expressed. All
four arrestins share high sequence and structural homology, consisting
out of an N-terminal and C-terminal domain built almost completely
from antiparallel β sheets, but still they preserve highly different func-
tional capabilities [7].
The initially discovered function of β-arrestins was regulation of
GPCR desensitization which leads to termination of the signal from
the activated receptor. In the classical desensitization mechanism
the agonist-occupied receptors are first phosphorylated by G protein-
coupled receptor kinases (GRKs) or second messenger-dependent pro-
tein kinases, e.g. protein kinase A (PKA) and protein kinase C (PKC),
mainly in the C-terminus but also in the intracellular loops. In the sec-
ond step, multifunctional adaptor proteins, β-arrestins, are recruited
to the activated and phosphorylated receptors. Binding of β-arrestins
inhibit further G protein coupling to the receptor thus leading to desen-
sitization. Subsequently, the receptor is internalized as a consequence of
recruitment byβ-arrestins key components of the endocyticmachinery,
including clathrin, adaptin and dynamin. Internalized receptors can be
either recycled back to the plasma membrane (resensitization) or de-
graded (down-regulation) [7–10].
Besides their function in receptor desensitization and trafficking, β-
arrestins are also able to induce signaling by scaffolding signalingmole-
cules such as p44/42 mitogen-activated protein kinase (p44/42MAPK),
c-Jun-N-terminal kinase 3 (JNK3), non-receptor tyrosine kinase c-Src,
p38 and AKT [11–13]. The discovery of β-arrestin-mediated signaling
brought a new appreciation of biased agonism. Biased agonism is best
explained as a model in which different GPCR active conformations
are either able to promote the full range of receptor activities or only a
restricted subset of them. The balanced ligands stabilize the conforma-
tions that allow for signaling to all downstream pathways, whereas bi-
ased ligands stabilize those conformations that promote only a part of
the signaling effects [14–19]. Currently, the bias agonism concept and
the possibility to create ligands, which exclusively activate β-arrestin-
mediated or G protein-mediated signaling are gaining increasing inter-
est due to their possible therapeutic applications. As an example the dis-
covery of β-arrestin–biased D2R ligands can be mentioned. Those
ligands seem to display potent antipsychotic-like activity without in-
ducingmotoric side effects which is desired in the therapy [20]. Recent-
ly, also a G-protein–biased D2R ligand was identified which will be
helpful in the elucidation of physiological effects mediated by G
protein- or β-arrestin-mediated signaling pathways and their involve-
ment in the therapeutic effects of various pharmaceutical agents [21].
An additional level of GPCR regulation by β-arrestins is achieved by
their ability to control GPCR ubiquitination. Several studies have
demonstrated that β-arrestins can interact with E3 ubiquitin ligases
and mediate ubiquitination of GPCRs, other cell surface receptors and
non-receptor proteins [22,23]. The initial study performed by Shenoy
and coworkers [24] has shown that stimulation of the β2-adrenergic re-
ceptor (β2AR) leads to receptor ubiquitination and degradation. The
presence of β-arrestin 2 and the ubiquitin ligase MDM2 was important
for this process, althoughMDM2 turned out to ubiquitinate β-arrestin 2
and not the receptor. Later work has revealed that β-arrestin 2 also in-
teracts with another ubiquitin ligase, neural precursor cell expresseddevelopmentally downregulated protein 4 (Nedd4), which is responsi-
ble for the ubiquitination and lysosomal degradation of β2AR [25].
The adaptor role of β-arrestins for ubiquitination of the μ-opioid and
V2 vasopressin (V2R) receptors was also reported, but the identity of the
E3 ligase is not known yet [26,27]. On the contrary, there are also exam-
ples such as the C-X-C chemokine receptor type 4 (CXCR4) which un-
dergo β-arrestin-independent ubiquitination [28].
In addition to ubiquitin ligases, β-arrestins can also interact with
deubiquitinating enzymes (DUBs), including ubiquitin-specific prote-
ases (USPs). USP33 was identified as a β-arrestin-interacting protein
in a yeast two-hybrid screen [29] and functions as an endogenous inhib-
itor of β-arrestin-dependent signaling initiated by β2AR. USP33 and
USP20 were also shown to regulate post-endocytic fate of internalized
β2AR.
1.3. KLHL12 a BTB-Kelch protein
KLHL12 is a member of the KLHL protein family. There are 42 mem-
bers of this family encoded in the human genome and all of them share
structural similarity. They all consist of an N-terminal BTB domain (bric
à brac 1, tramtrack, and broad-complex), a central BACK domain and
5–6 Kelch motifs at the C-terminus. KLHL proteins are known to be
involved in the process of ubiquitination and in most cases they
serve as adaptors for Cullin3-based E3 ligases [30]. As such, they
can also bind to multiple substrates for ubiquitination. For example
KEAP1 (KLHL19) has at least three different substrates: NRF2, IKKβ
and BCL-2 [31]. Besides toD4R, KLHL12was described to bind [32] toDi-
shevelled [33] and SEC31, the COPII vesicle component [34] and in all
cases KLHL12 functions as an adaptor for the Cullin3-based E3 ligase
and targets proteins for ubiquitination. Polyubiquitination of Dishev-
elled leads to its degradation which antagonizes the Wnt-β-catenin
pathway [33]. In case of SEC31, the KLHL12-Cullin3 E3 ligase complex
promotes monoubiquitination which regulates formation of the large
COPII vesicles important for the export of collagen from cells [34].
In our previous studies we have shown that KLHL12 interacts with
the D4R and functions as an adaptor in the Cullin3-based E3 ligase com-
plex and in this way enhances ubiquitination of the receptor. The in-
creased ubiquitination of the D4R, however, does not promote its
degradation [32,35]. Moreover, it was also reported that stimulation of
the D4R does not lead to β-arrestin recruitment and receptor internali-
zation [36].
In the current study we show that both β-arrestins bind constitu-
tively with all common D4R variants as well as with KLHL12 and that
these three proteins can co-exist in one complex. However, stimulation
of the receptor does neither influence association between these pro-
teins, nor their cellular distribution. Interestingly, the E3 ligase complex
member Cullin3 also co-precipitates with both β-arrestins but has no
influence on their ubiquitination.
Asβ-arrestins can function as scaffolds for E3 ligases, the importance
of β-arrestins for the interaction between D4R and KLHL12 and
ubiquitination of D4Rwas verified. Additionally, we have also examined
if KLHL12 has an influence on p44/42 MAPK phosphorylation, the sig-
naling pathway which is often mediated by β-arrestins, but no signifi-
cant effect was observed.
2. Materials and Methods
2.1. Plasmids and antibodies
HAD4.0R, HA D4.2R, HA D4.4R, HA D4.7R, HA D4.2 ΔΔR, HA Cullin3, Etag
KLHL12, Etag KLHL12ΔKelch (aa 1–280), Etag KLHL12ΔBTB (aa 118–
568), Flag KLHL12 were described before [32]. The coding sequence of
BTB domain of KLHL12 was amplified from the pOTB7-KLHL12 Vector
(I.M.A.G.E. Clone ID: IRAL p962K062) by PCR using primers anchored
with NotI and XhoI recognition sequences. The NotI-XhoI fragment was
cloned into the NotI-XhoI sites of the Etag pCAGGS/A20 vector to
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cloning strategy are available upon request. The Etag Kelch (aa 277–
568) construct was obtained by digesting Etag KLHL12 with AvrII,
treating with Klenow fragment and next digesting with XhoI and DraI.
This sequence was later cloned to the Etag pCAGGS/A20 vector treated
with NotI, Klenow fragment and XhoI, respectively. The integrity of all
constructed KLHL12 vectors was confirmed by sequence analysis.
Flag β-arrestin 1, Flag β-arrestin 2, β-arrestin1-GFP, β-arrestin2-GFP
were described before [36]. Flag β-arrestin 2 NT encoding the N-
terminal domain of β-arrestin 2 (aa 1–320) and Flag β-arrestin 2 CT
encoding the C-terminal domain of β-arrestin 2 (aa 284–409), were
kind gifts from Prof. Dr. R. Lefkowitz (Duke University, Durham, NC).
Primary antibodies used were mouse monoclonal anti-HA
(clone16B12; Covance Research Products), rabbit anti-Etag (Abcam),
rabbit anti-HA (GeneTex), rat anti-HA (Roche), mouse monoclonal
anti-Flag M2 (Sigma), rabbit anti-phospho-p44/42 MAPK (Cell Signal-
ing), mouse anti-p44/42 MAPK (Cell Signaling), mouse anti-tubulin
(Sigma).
Secondary antibodies used were goat anti-rabbit IRDye680 LT, goat
anti-mouse IRDye680 LT, goat anti-mouse IRDye680 RD (used for in-
cell-western), goat anti-rabbit IRDye800, goat anti-mouse IRDye800,
goat anti-rat IRDye680 LT and were all purchased from LI-CORFig. 1. β-arrestin 1 and β-arrestin 2 interact with all common D4R polymorphic variants H
harvested and lysed. Part of the lysate was used for IB to verify expression of HA-tagged rece
subjected to IP with anti-Flag. Specific purification of both β-arrestins after IP was confirme
with anti-HA. Data shown are representative of four independent experiments.Biosciences. Secondary antibodies used for immunofluorescence
were: Alexa Fluor 350 donkey anti-mouse, Alexa Fluor 594 donkey
anti-rabbit (Invitrogen).2.2. Cell culture and transfection
HEK293T cells and MEF cells were cultured in Dulbecco's modified
Eagle's medium (DMEM; Invitrogen), supplemented with 10% fetal
calf serum, penicillin (100 U/ml), and streptomycin (100 μg/ml) in a
controlled environment (37 °C, 98% humidity, 5% CO2). For co-
immunoprecipitation experiments HEK293T cells were transfected
using the Polyethylenimine (PEI) method as described before [35]. A
total amount of 10 μg of DNA was used for transfection of cells in one
10-cm dish.
For immunofluorescence experiments HEK293T cells were
transfected using calcium phosphate method [35].
HEK293S cells stably expressingHAD4.2R or HAD4.0Rwere grown in
DMEM/F12 (Gibco, Invitrogen) supplementedwith 10% fetal calf serum,
penicillin (100 U/ml), streptomycin (100 μg/ml), and 0.5 mg/ml G418
(Geneticin, Gibco) in a controlled environment (37 °C, 98% humidity,
5% CO2). The PEI method was also used for transient transfection.EK293T cells were transiently transfected as indicated. 48 h post-transfection, cells were
ptors and Flag β-arrestin 1 (A) or Flag β-arrestin 2 (B). The remainder of the lysate was
d upon IB with anti-Flag. Interaction of D4R variants with β-arrestins was verified by IB
Fig. 2. KLHL12 interacts with β-arrestin 1 and β-arrestin 2 HEK293T cells transiently
transfected as indicated were lysed 48 h post-transfection. 5% of the lysate was used for
IB to verify expression of Etag KLHL12 and Flag β-arrestin 1 (A) or Flag β-arrestin 2 (B).
The remainder of the lysate was used for IP with anti-Flag. Specific purification of
β-arrestins was confirmed upon IB with anti-Flag, whereas co-immunoprecipitation
of KLHL12 was revealed upon IB with anti-Etag. The results shown are representative
of three independent experiments.
1004 K. Skieterska et al. / Cellular Signalling 28 (2016) 1001–1014MEF cells were transfected using Lipofectamine® 2000 (Invitrogen)
(3μl/μg DNA) according to the manufacturer's instruction with 25 μg of
total DNA used for transfection of cells in one 10-cm dish.
2.3. Co-immunoprecipitation (co-IP)
Forty eight hours after transfection cells were washed twice with
cold phosphate-buffered saline (PBS), harvested and the cell pellet
was frozen at−70 °C for at least 1 h before lysis. Cell lysates were sub-
jected to immunoblot analysis, or to immunoprecipitation (IP) followed
by immunoblotting (IB), as described before [37].
2.4. Ubiquitination assay – sequential double immunoprecipitation
Ubiquitination assay was described before [38]. Briefly, cells were
lysed in radioimmunoprecipitation buffer (RIPA) supplemented addition-
ally with the inhibitor of deubiquitinating enzymes, N-ethylmaleimide
(NEM). For the first IP, 2 μg of anti-HA (16B12) antibody or 10 μl of HA-
beads (Sigma)were used and sampleswere incubated overnightwith an-
tibody and agarose beads. Next, three wash steps with the lysis buffer
were performed and proteins bound to the beads (receptor and
interacting partners) were eluted under denaturing conditions, and
a quarter of the eluate was used to confirm the first IP. The remainder
of the eluate, containing denatured proteins, was diluted with lysis
buffer and subjected to a second IP to remove receptor-interacting
proteins from the first IP and specifically isolate the protein of inter-
est. Finally, the eluates from the second IP were subjected to immu-
noblotting for the detection of ubiquitinated receptor.
2.5. Single-molecule pull-down assay (SIMPull)
a) Lysate preparation
HEK293T cells were grown in 12-well plates and transfected using
the PEI method, first with Flag-D4.4R (300 ng) and Venus-KLHL12
(600 ng). 24 h later, the transfection complex was removed and cells
were further transfected overnight with mCherry-βarrestin 2 (300 ng).
Cells sequentially transfected with Venus-KLHL12 and mCherry-
βarrestin 2, but without Flag-D4.4R, served as negative control. Next,
cells were lysed with 200 μl/well of lysis buffer (150 mM NaCl, 10 mM
Tris-HCl pH 7.4, 2 mMEDTA, 1% NP40, 1.5mMMgCl2, with protease in-
hibitors). Lysates were clarified by centrifugation (13,000 g, 15 min,
4 °C).
b) Single-molecule pull-down
SIMPull slides containing chambers were prepared according to the
protocol described in [39]. Chambers were first washed twice with T50
buffer (10 mM Tris/HCl pH 7.8; 50 mM NaCl). Next, NeutrAvidin
(Thermo) was added and slides were incubated for 5 min. After wash-
ing, biotinylated anti-Flag antibody (~ 10 nM) was added (10 min incu-
bation at RT). Subsequently, undiluted cell lysateswere added, followed
by 20 min incubation at RT. Unbound antibodies and sample were re-
moved from the chamber by washing with T50 buffer twice between
successive additions. Proteins immobilized on the slideswere visualized
by a prism type total internal reflection fluorescence (TIRF) microscope
equipped with excitation laser 488nm (Venus) and 561nm (mCherry),
and DV2 dichroic 565dcxr dual-view emission filters (520/30nm and
630/50nm). In all cases, mCherry fluorescence was collected first,
followed by Venus fluorescence at the same position. Mean spot
counts per image and standard deviations were calculated from
images taken from 5 to 10 different regions. Single-molecule
colocalization between Venus and mCherry was calculated based
on pictures from two different channels, the Venus channel (ex.
488 nm, em. 520/30 nm) and the mCherry channel (ex. 561 nm,em. 630/50 nm), made at exactly the same imaging area using a
method described previously [40]. The mCherry and Venus mole-
cules within a 2-pixel (~300 nm) distance were considered as
colocalized. The number of molecules where colocalization occurred
divided by the total number of mCherry molecules was calculated as
overlap percentage.
2.6. Immunofluorescence microscopy
HEK293 cells were seeded in wells with coverslips and
transfected using the calcium phosphate method in a 5:5:1 ratio of
the expression plasmids for Flag KLHL12:HA receptor:β-arrestin1/
2-GFP. Immunocytochemistry was performed as described previous-
ly [36].
2.7. Detection of p44/42 mitogen-activated protein kinase (MAPK) phos-
phorylation by in cell western
HEK293S cells stably expressing HA D4.2R or HA D4.0R were grown
and transiently transfected on 10-cm dish using PEI method. 6 h post-
transfection cells were reseeded to poly-D-lysine coated 96-well plates.
24 h later, medium on the cells was replaced with serum free medium
with orwithout 100 ng/ml of pertussis toxin (PTX). After 18 h of incuba-
tion, cells were treatedwith 100 nMPD 168077 for 1 to 90min at 37 °C.
Incubation was stopped by removing the culture medium, followed by
addition of fixing solution (3.7% formaldehyde in PBS) for 20 min at
room temperature (RT). Next, cells were permeabilized by washing 4
times for 5 min with Triton washing solution (0.1% Triton X-100 in
PBS). Subsequently, cells were blocked with a blocking buffer (LI-COR
Biosciences) for 90 min and finally, cells were incubated overnight at
4 °C with two primary antibodies: rabbit anti-phospho-p44/42 MAPK
and mouse anti-p44/42 MAPK diluted in the blocking buffer. The next
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solution (0.1% Tween-20 in PBS) and incubated with fluorescently la-
beled secondary antibodies: goat anti-rabbit IRDye800 and goat anti-
mouse IRDye680 RD for 1 h at RT. After final washing with TweenFig. 3. Kelch repeats of KLHL12 are involved in the interaction with β-arrestins HEK 293T c
and lysed. Part of the lysate was used for IB to verify expression of full length Etag KLHL12, KLH
the lysate was subjected to IP with anti-Flag. Specific purification of both β-arrestins after IP w
β-arrestins was verified by IB with anti-Etag. The results shown are representative of three (β
the wild type KLHL12 protein and deletion mutants used in this study. The depicted sequenceswashing solution, the fluorescent signal was detected with the Odyssey
Infrared Imaging system. In the analysis, background values of the sec-
ondary antibody are subtracted and the phospho-p44/42 MAPK signal
is normalized against the total p44/42 MAPK signal.ells were transiently transfected as indicated. 48 h post-transfection, cells were harvested
L12 deletion mutants and Flag β-arrestin 1 (A) or Flag β-arrestin 2 (B). The remainder of
as confirmed upon IB with anti-Flag. Interaction of KLHL12 WT or deletion mutants with
-arrestin 2) and two (β-arrestin 1) independent experiments. C) Schematic illustration of
were fused to an N-terminal Etag.
Fig. 5. D4R, KLHL12 and β-arrestin 2 form a trimeric complexHEK293T cells expressing Flag D4.4R, KLHL12-Venus and β-arrestin 2-mCherry (specific pull-down) or KLHL12-Venus and
β-arrestin 2-mCherry (background) were lysed and the lysates were applied to the microscope slide containing chambers coated with biotinylated anti-Flag antibody or without coating
(background). Slides were imagedwith the single-molecule prism-type TIRF microscope to verify co-precipitation of β-arrestin 2-mCherry and KLHL12-Venus. A) Schematic representa-
tion of the protein complex investigated in this study. B) Example of single triple-complex image. The upper row shows specific pull-down of KLHL12-Venus (green) and β-arrestin 2-
mCherry (red) where lysate was applied to a chamber coated with biotinylated anti-Flag antibody. The lower row shows non-specific binding (background) of KLHL12-Venus and β-
arrestin 2-mCherry to the slide which was not coated with the antibody. In the merged picture the colocalization between the two molecules is visible as yellow puncta. C) Mean spot
counts per image and standard deviations were calculated from images taken from 5 to 10 different regions of the imaging surface. D) Single-molecule colocalization between Venus
andmCherrywas performed using amethod described previously [40], themCherry and Venusmolecules within a 2-pixel (~300 nm) distance were considered as colocalized. The num-
ber of molecules where colocalization occurred divided by the total number of mCherry molecules was calculated as overlap percentage. The results shown are representative of three
independent experiments.
Fig. 4. KLHL12 interactswith the C-terminal domain ofβ-arrestin 2 48h post-transfectionHEK293T cellswere harvested and lysed. Part of the lysatewas used for IB to verify expression
of Etag KLHL12 and Flag-tagged full length β-arrestin 2, β-arrestin 2 C- (CT) or N-terminal (NT) deletion mutants. The remainder of the lysate was subjected to IP with anti-Flag. Specific
purification ofβ-arrestins after IPwas confirmedupon IBwith anti-Flag. Interaction of KLHL12withβ-arrestin 2WT and deletionmutantswas verifiedby IBwith anti-Etag. Data shown are
representative of three independent experiments.
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3.1. β-arrestin 1 and β-arrestin 2 constitutively interact with all common
D4R variants
In our previous study [36] it was shown that the D4.2R interacts with
β-arrestin 2 and that stimulation of the receptor with its agonist, dopa-
mine, has no influence on the association betweenD4R and β-arrestin 2.
As mentioned before, the D4R has an important polymorphism in its
IC3where a 16 amino acid sequence is repeated two to eleven times giv-
ing rise to different polymorphic variants. Althoughmany variants exist,
the D4.4R (64%), D4.7R (21%), andD4.2R (8%) are themost frequent in the
human population [5]. Therefore, the binding of β-arrestin 1 and
β-arrestin 2 to all these polymorphic variants was verified by co-IP. Ad-
ditionally, we have tested possible interaction with D4.0R, an artificial
receptor variant from which the polymorphic repeats were removed.
The results presented in Fig. 1 clearly show that both β-arrestins inter-
act with all tested receptor variants even without stimulation with an
agonist. Co-immunoprecipitation of β-arrestins with D4.0R, which does
not contain the polymorphic repeats in the IC3, suggests that theFig. 6. Dopamine stimulation has no influence on the interaction between β-arrestin 1 or
transfection, cells were treated with 10 μM dopamine (DA) for 1 to 30 min (as indicated) and
verify expression of Etag KLHL12, HA D4.2R and Flag β-arrestin 1 (A) or Flag β-arrestin 2 (B). Th
arrestins after IPwas confirmed upon IBwith anti-Flag. Interaction of KLHL12with β-arrestins w
HA. The results shown are representative of three (β-arrestin 2) and two (β-arrestin 1) indepepolymorphism-containing domain is not required for the interaction
between D4R and β-arrestins. Binding of β-arrestins often requires
phosphorylation of the intracellular part of the receptor [19,41,42].
We have identified before [36], by mass spectrometry, two serines:
Ser239 and Ser245, which are phosphorylated in the D4R and their phos-
phorylation does not depend on agonist stimulation of the receptor. To
verify if these two serines play a role in β-arrestin binding, the interac-
tion between both β-arrestins and the D4.2 ΔΔR mutant was tested. In
this mutant the regions: aa 233–253 (just before the polymorphic re-
peats) and aa 283–307 (just after the polymorphic repeats) are deleted.
Although in the D4.2 ΔΔR both serines are missing the receptor can still
interact with both β-arrestins suggesting that phosphorylation of
these two residues is not crucial for the interaction between the re-
ceptor and β-arrestins. It is worth to mention that previously it was
already reported that GRK2 can constitutively regulate D2R expres-
sion and signaling independently of receptor phosphorylation [43].
The suppression of receptor expression was correlated with consti-
tutive association of GRK2 with the receptor complex which did
not depend on the phosphorylation of the receptor and was not en-
hanced by agonist stimulation.2 and KLHL12 or D4R HEK293T cells were transiently transfected as indicated. 48 h post-
next, washed twice with cold PBS, harvested and lysed. 5% of the lysate was used for IB to
e remainder of the lysate was subjected to IPwith anti-Flag. Specific purification of both β-
as verified by IBwith anti-Etag and co-purification of D4.2R was visualized by IBwith anti-
ndent experiments.
Fig. 7. Cullin3 forms a complex with both β-arrestin 1 and 2 HEK 293T were transiently transfected as indicated. 48 h post-transfection cells were lysed. 5% of the lysate was used to
verify expression of Etag KLHL12, HA Cullin3 and Flag-tagged β-arrestin 1 and 2. The remainder of the lysate was subjected to IP with anti-Flag. Specific purification of both β-arrestins
after IP was confirmed upon IB with anti-Flag. Interaction of Cullin3 with β-arrestins was verified by IB with anti-HA. Co-purification of KLHL12 was checked by IB with anti-Etag. The
results shown are representative of three independent experiments.
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KLHL12 is a protein that specifically binds to the polymorphic region
in the D4R and promotes ubiquitination of the receptor [32]. β-arrestins
aremultifunctional proteinswhich can function as adaptors for E3 ubiq-
uitin ligases and be involved in regulation of protein ubiquitination [23].
To verify if β-arrestins play a role in ubiquitination of the D4R, the inter-
action between KLHL12 and β-arrestin 1 and 2 was verified. Co-IP stud-
ies performed in HEK293T cells show a clear interaction between both
β-arrestins and KLHL12 (Fig. 2).
To further characterize this novel interaction between KLHL12 and
β-arrestins we investigated which regions of KLHL12 are involved in
the interaction. Co-IP studies in HEK293T cells using deletion mutants
of KLHL12 (Fig. 3C) showed that deletion of the BTB region does notFig. 8. Dopamine stimulation and Cullin3 overexpression do not influence β-arrestin 1 and
were treatedwith 10 μMdopamine for 5 to 20min (as indicated), washed twicewith cold PBS, ha
V5 Cullin3 and (Cmyc Ub)n-proteins. The remainder of the lysatewas subjected to double sequen
first and second IPwas verified by IBwith anti-FlagDyLight 800,whereas their ubiquitinationwas
examined after the first IP by IB with mouse anti-V5 and rat anti-HA, respectively. The results shdisrupt the interaction with β-arrestin 1 (Fig. 3A) and β-arrestin2
(Fig. 3B), since co-IP of the KLHL12ΔBTB and Kelch mutant with both
β-arrestins could be clearly detected. In contrast, by deleting the Kelch
domain from KLHL12, interaction with both β-arrestins is completely
abolished. These results suggest that the Kelch domain of KLHL12, but
not the BTB domain, is sufficient and required for the interaction with
β-arrestin 1 and β-arrestin 2. Of interest, it was also demonstrated be-
fore that the Kelch repeats are important for the interaction of KLHL12
with D4R [32].
Similarly, wewanted to pinpoint the region in β-arrestins important
for the interaction with KLHL12. β-arrestins have two conserved do-
mains: the N-, and C-terminal domain. Co-IP studies with β-arrestin 2
C- or N-terminal deletion mutants revealed that KLHL12 can bind with
the C-terminal domain of β-arrestin 2 (Fig. 4).2 ubiquitinationHEK293T cells were transfected as indicated. 48 h post-transfection, cells
rvested and lysed. 5% of the lysatewas used to verify expression of HAD4.2R, Flagβ-arrestins,
tial IPwith agarose beads coupled tomouse anti-Flag. Specific purification ofβ-arrestins after
revealed upon IBwith rabbit anti-Cmyc. Interaction of Cullin3 andD4.2Rwithβ-arrestinswas
own are representative of two independent experiments.
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the C-terminal domain of β-arrestin 2 are important for the interaction
between these proteins.
3.3. D4R, KLHL12 and β-arrestin 2 form a trimeric complex
In order to verify if D4R, KLHL12 and β-arrestins form a trimeric
complex a single-molecule pull-down (SIMPull) analysis was per-
formed. SIMPull is a new technique which allows studying cellular
protein complexes with single-complex resolution. In this method
macromolecular complexes are pulled down from cell or tissue ex-
tracts directly to the imaging surface of a single-molecule fluores-
cence microscope [40].
The HEK293T cells transiently expressing Flag D4.4R, KLHL12-Venus
and β-arrestin 2-mCherry were used. After cell lysis, Flag D4.4R together
with its interacting partners was pulled down using biotinylated anti-
Flag antibody (Fig. 5). The slide was imaged with the single-molecule
TIRF microscope and the number of spots (molecules) representing
co-immunoprecipitated β-arrestin 2-mCherry and KLHL12-Venus wasFig. 9. β-arrestin 1 or β-arrestin 2 are not important for the interaction between D4R and
transfected as indicated. 48 h post-transfection cells were harvested and lysed. 5% of the lysa
β-arrestin 2. The remainder of the lysate was subjected to IP with mouse anti-HA. Specific p
KLHL12 with the receptor was revealed by IB with rabbit anti-Etag. * Indicates Etag KLHL12
representative of three independent experiments.calculated (Fig. 5C). Non-specific binding of both fluorescently labeled
proteins (β-arrestin 2-mCherry and KLHL12-Venus) was verified by ap-
plying lysate from the cells expressing β-arrestin 2-mCherry and
KLHL12-Venus alone to the chamber or by applying lysates of cells ex-
pressing all three proteins to the chamber which was not coated with
the biotinylated anti-Flag antibody. As shown in Fig. 5C a very signifi-
cant pull-downof KLHL12-Venus andβ-arrestin 2-mCherrywas obtain-
ed compared to the background samples. Next, the percentage of
colocalization between the spots representing β-arrestin 2-mCherry
and KLHL12-Venus was calculated (Fig. 5D).
Our results show that about 40% of β-arrestin 2-mCherry molecules
colocalize with KLHL12-Venus suggesting that D4R, KLHL12 and
β-arrestin 2 can exist in a trimeric complex. Although this percentage
of colocalization may seem low, it has to be taken into account that
GFP has been reported to have ~75% fluorescently active and ~25% fluo-
rescently inactivemolecules among total GFP proteins expressed in cells
[40,44]. Assuming that mCherry and Venus have similar fluorescently
active ratios as GFP, then the maximal colocalization percentage
calculated based on fluorescent observation is 60% rather than 100%.KLHL12WTMEF cells and MEF cells with knockout of β-arrestin 1 or β-arrestin 2 were
te was used to verify expression of HA D4.2R, Etag KLHL12 and Flag β-arrestin 1 or Flag
urification of the receptor after IP was verified by IB with rabbit anti-HA. Interaction of
visible on the blot as both antibodies used for IB were of rabbit origin. Data shown are
1010 K. Skieterska et al. / Cellular Signalling 28 (2016) 1001–1014Therefore, the incomplete colocalization in the assay thus arises mainly
from inactive chromophores and unbalanced expression of twoproteins
in individual cells.
3.4. Dopamine stimulation has no effect on the interaction of KLHL12 with
β-arrestin 1/2
β-arrestin 1 and β-arrestin 2, as well as KLHL12, interact constitu-
tively with D4R [32,36].
The fact that D4R, KLHL12 and β-arrestin 2 can exist as a trimeric
complex encouraged us to further investigate whether KLHL12 and
β-arrestins cooperate to regulate D4R functionality.
β-arrestins are known to regulate ubiquitination of GPCRs
through binding with different proteins like E3 ubiquitin ligases or
deubiquitinating enzymes and this complicated regulatory mechanism
is often initiated by stimulation of the receptor. For example, USP33 is
pre-coupled toβ2AR but upon stimulation dissociates from the receptor
and associates with β-arrestin 2. Therefore, we were interested if
stimulation of the receptor with an agonist has an influence on the in-
teraction between β-arrestins and KLHL12. To answer this question,
Flag β-arrestin 1 and Flag β-arrestin 2 were immunoprecipitated from
HEK293T cells which were treated with dopamine for various time
points. Stimulation of the receptor for 1 to 30min did not cause any sig-
nificant changes in the level of co-precipitated Etag KLHL12 (Fig. 6). This
observation suggests that stimulation of the receptor does not influence
the interaction between KLHL12 and β-arrestins. Moreover, in the same
experiment no influence of receptor stimulation on its association with
β-arrestins was observed. The latter observation is in agreement with
our previous findings in which the resistance of D4R to agonist induced
β-arrestin recruitment, internalization and desensitization was de-
scribed [36]. In that studywe have investigated the interaction between
D4R and β-arrestins using co-immunoprecipitation and also immuno-
fluorescence studies were performed to visualize recruitment of β-Fig. 10. KLHL12 enhances D4R ubiquitination in β-arrestin 1 and β-arrestin 2 knockout M
transfected as indicated. 48 h post-transfection cells were harvested and lysed. 5% of the lysa
remainder of the lysate was subjected to double sequential IP with agarose beads coupled to
with rat anti-HA whereas receptor ubiquitination was revealed upon IB with anti-Flag-HRP. *
mouse antibody used for IP is detected by the anti-rat secondary antibody due to cross-reactivarrestins to the plasma membrane and internalization of the receptor.
Similar results were also described by Cho and colleagues [45] who in-
vestigated β-arrestin recruitment upon dopamine activation of five
different dopamine receptors. They observed robust β-arrestin 2 re-
cruitment to the plasma membrane in the cells expressing D1R, D2R
and D5R, however, hardly any effect was noticed when D3R or D4R
were activated. On the other hand several recent studies described re-
cruitment of β-arrestin 2 upon D4R activation measured using novel
assays including the Presto-TANGO assay in which lisurdine was used
as D4R agonist [46]; BRET assay in which additionally GRK 2 was
overexpressed to promote receptor phosphorylation and β-arrestin 2
recruitment [47]; and PathHunter assay fromDiscoverXwhichwas per-
formed in CHO cells stably expressing D4R [48]. The contradictory re-
sults observed by these groups cannot be easily explained but the use
of other cell lines, ligands and overexpression of additional signaling
molecules may play an important role.
3.5. Cullin3, member of the E3 ubiquitin ligase complex which ubiquitinates
D4R, interacts also with β-arrestin 1 and β-arrestin 2
KLHL12 functions as an adaptor protein between D4R and the Cullin3-
based E3 ubiquitin ligase and in this way promotes ubiquitination of the
receptor. For some GPCRs, e.g. β2AR [24] ubiquitination of β-arrestins
is required for subsequent ubiquitination, internalization and degrada-
tion of the receptor. It was shown before by us [35] that overexpression
of KLHL12 has no influence on ubiquitination of β-arrestin 2. Now, we
were interested if Cullin3 is also present in the complex with KLHL12
and β-arrestins. Fig. 7 shows that Cullin3 is co-immunoprecipitated
with β-arrestin 1 and also with β-arrestin 2, although for the latter
the signal is significantly weaker. Similarly, more KLHL12 is co-
immunoprecipitated with β-arrestin 1 than with β-arrestin 2.
Next, it was examined if Cullin3 has an influence on the ubiquitination
ofβ-arrestins. The ubiquitination assaywas performed inHEK293T cellsEF cells.WTMEF cells and MEF cells with knockout of β-arrestin 1 or β-arrestin 2 were
te was used to verify expression of HA D4.2R, Etag KLHL12 and (Flag Ub)n-proteins. The
mouse anti-HA. Specific purification of the receptor after the second IP was verified by IB
Association of two heavy chains of mouse anti-HA antibody (each 50 kDa), the primary
ity. The results shown are representative of two independent experiments.
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periment HA D4R was overexpressed and cells were incubated for dif-
ferent time points with D4R agonist, dopamine, to test if stimulation ofFig. 11. Stimulation of D4R with dopamine has no influence on cellular distribution of KLH
pHA D4.2R, or pHA D2R as a positive control, pFlag KLHL12 and pβ-arrestin1-GFP or pβ-arrestin2
anti-HA and subsequently, cells were induced with dopamine (DA, 10 μM, 30min). Next, cells w
were incubated with fluorescent secondary antibodies, anti-mouse Alexa 350 and anti-rabbit
overlay picture. The results shown are representative of three independent experiments.the receptor promotes or inhibits interaction between β-arrestins and
Cullin3. The obtained results (Fig. 8) do not reveal any differences
in association between both β-arrestins and Cullin3 upon D4RL12 and β-arrestins HEK293T were seeded in wells with coverslips and transfected with
-GFP in a 5:5:1 ratio. 48 h post-transfectionmembrane receptors were labeled with rabbit
ere fixed, permeabilized and Flag KLHL12was labeled with mouse anti-Flag. Finally, cells
Alexa 594. Receptors are visualized in red, KLHL12 in blue and β-arrestins in green in the
Fig. 12. Pretreatment of cells with pertussis toxin abolishes completely p44/42
MAPK phosphorylation upon D4R stimulation and KLHL12 does not influence
phosphorylation of this kinase significantly HEK293S cells stably expressing HA
D4.2R and HA D4.0R were transiently transfected with Etag KLHL12 or empty vector
(pcDNA3). After overnight starvation in serum free medium with or without addition
of pertussis toxin, cells were incubated with specific D4R agonist PD 168077 (100 nM)
for 1 to 90 min. An in-cell-western assay was performed and phosphorylated p44/42
MAPK was detected with rabbit anti-phospho p44/42 MAPK. Values were normalized
against the signal detected with mouse anti-p44/42 MAPK. Graphs show results from
three independent experiments performed in triplicate (mean ± SEM).
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and 2 was observed. Taken together, all these data, indicate that ac-
tivation of D4R does not promote binding of Cullin3 to β-arrestins,
or the ubiquitination of β-arrestins. Overexpression of Cullin3 also
does not influence ubiquitination of β-arrestins suggesting that
β-arrestins probably do not function as substrates for Cullin3-
mediated ubiquitination but rather as adaptor proteins which recruit
Cullin3 to other target proteins.
3.6. β-arrestin 1 and β-arrestin 2 are neither required for the interaction
between D4R and KLHL12, nor for KLHL12-mediated ubiquitination of the
D4R
The presence of Cullin3 in the complex further suggests the im-
portance of β-arrestins in ubiquitination of D4R. To examine this pos-
sibility, it was first tested if β-arrestins are necessary for the
interaction between D4R and KLHL12. β-arrestins are ubiquitously
expressed proteins and therefore, co-IP experiments were per-
formed in MEF cells with knockout of β-arrestin 1 or β-arrestin 2 de-
scribed before [49] and the results were compared with those
obtained from WT MEF cells (Fig. 9). Etag KLHL12 was clearly co-
immunoprecipitated in MEF cells with knockout of β-arrestin 1 or
β-arrestin 2 suggesting that β-arrestins do not function as scaffolds
between D4R and KLHL12 and are not critical for the interaction be-
tween these two proteins. We cannot exclude the possibility that
there is a redundancy between the two β-arrestins, as we were un-
able to obtain conclusive results from the MEF cells with a double
knockout of β-arrestin 1 and β-arrestin 2 due to too low transfection
efficiency.
Although β-arrestins seem not to be required for the interaction be-
tweenD4R andKLHL12 they can still be involved in the ubiquitination of
the receptor. To examine this hypothesis, we have performed a
ubiquitination assay in WT MEF cells and MEF with knockout of either
β-arrestin 1 or β-arrestin 2 (Fig. 10). In all tested cell lines KLHL12
could still enhance ubiquitination of D4R which suggests that KLHL12-
mediated ubiquitination of D4R does not depend on the presence or
activity of β-arrestins. Of course, as mentioned before, redundancy be-
tween the two β-arrestins cannot be ruled out.
3.7. Stimulation of D4R does not influence the subcellular distribution of
KLHL12 and β-arrestins
β-arrestins are common regulators of GPCR internalization and
down-regulation. Upon receptor stimulation β-arrestins are recruited
to the plasma membrane to form a complex with the receptor and to
further assist during its internalization. To examine whether the com-
plex formed between D4R, β-arrestin 1 or 2 and KLHL12 plays a role in
receptor internalization, the cellular distribution of all three proteins
with or without stimulation of the receptor was investigated by im-
munofluorescence studies. HA D4.2R, Flag KLHL12 and GFP tagged
β-arrestin 1 or 2 were transiently overexpressed in HEK293T cells.
48 h after transfection, the receptor on the plasmamembrane was la-
beled with specific antibodies followed by agonist treatment (10 μM
dopamine) for 30 min. Upon cell fixation and permeabilization, Flag
KLHL12 was labeled with primary antibody. Finally, the receptor-
antibody and KLHL12-antibody complexes were recognized by
anti-rabbit-Alexa 594 and anti-mouse-Alexa 350, respectively and
visualized together with GFP-tagged β-arrestins by fluorescence mi-
croscopy (Fig. 11). As a positive control, D2R was used. Cell surface
expressed D2R (visible at the plasma membrane in non-stimulated
cells) is clearly internalized upon treatment with dopamine (visible
as intracellular puncta in bottom panels). This confirms the activity
of the agonist and the presence of all required components of the
endocytic machinery, necessary to allow a typical agonist-induced
response in HEK293T cells. In contrast to D2R, no significant effect
of dopamine stimulation on the distribution of D4R was observed.We reported before that the D4R is resistant to agonist-induced re-
ceptor internalization and β-arrestin recruitment [36]. Here, we
have additionally investigated cellular distribution of KLHL12 and
both β-arrestins upon D4R stimulation but no significant changes in
their cell localization were detected. These results are also in agree-
ment with the co-IP studies presented in Fig. 6, showing that dopa-
mine stimulation does not seem to influence β-arrestin 1 and β-
arrestin 2 interactions with KLHL12 or D4R.
The atypical behavior of D4R upon agonist stimulation can also sug-
gest that the internalization of the D4R is regulated in another way, in-
dependent of β-arrestins. One of the possibilities is endophilin-
mediated endocytosis. The interaction between SH3 binding domains
in the IC3 of D4R and endophilinwas described recently [50] and the im-
portance of endophilin in the internalization of D4R was also demon-
strated in cells with endophilin knockdown.
Fig. 13. Schematic representation of the D4R – KLHL12 - β-arrestin complex KLHL12 interacts through its Kelch repeats with the polymorphic region of D4R and functions as adaptor
protein in a Cullin3-based E3 ligase complex to promote ubiquitination of D4R. β-arrestin 1 and 2 interact with: D4R in the region outside the polymorphic repeats; with the Kelch repeats
of KLHL12; with Cullin3, but it remains unknown if the KLHL adaptor protein is required for this interaction. Stimulation of D4R initiates phosphorylation of p44/42 MAPK which is
exclusively mediated by Gαi protein.
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exclusively by G proteins and KLHL12 does not play a role in this signaling
pathway
Signaling of GPCRs is mediated primarily by G proteins and by
β-arrestins leading to different outcomes. One of the frequently studied
signaling pathways that can be activated by both G proteins and
β-arrestins is the p44/42MAPK pathway. Itwas reported before that ac-
tivation of D4R leads to the phosphorylation of p44/42 MAPK [51]. We
wanted to investigate whether this signaling pathway is mediated
only by G proteins or if β-arrestins also play a role in this process and
whether KLHL12 or ubiquitination of the receptor influence agonist-
induced MAPK activation. D4R is coupled to Gαi proteins which func-
tions can be blocked by pertussis toxin. A series of MAPK phosphoryla-
tion assays was performed in HEK293 cells stably expressing HA D4.2R
or HA D4.0R which were transiently transfected with Etag KLHL12 or
empty vector (pcDNA3). First, cells were pretreated overnightwith per-
tussis toxin or left untreated and next, incubated with D4R specific ago-
nist, PD 168077 (100 nM), for different time points. β-arrestin-
mediated signaling of a GPCR is often slower than G protein-mediated
signaling [52] and therefore, incubation with the agonist for up to 90
min was performed. As shown in Fig. 12 for both D4.2R and D4.0R the
highest phosphorylation signal is detected after 3–5 min stimulation
with the agonist and the phosphorylation is completely abolished in
cells in which Gαi proteins are blocked by pertussis toxin. These results
suggest that phosphorylation of p44/42 MAPK upon D4R activation is
mediated exclusively by Gαi proteins and that β-arrestins do not seem
to be important in this process. Additionally, no significant effect of
KLHL12 overexpression was detected in these experiments. Taken
together, these observations suggest that the KLHL12-mediated
ubiquitination of D4R or interaction between KLHL12 and β-arrestins
do not play a role in the regulation of p44/42MAPKphosphorylation ini-
tiated by D4R.4. Conclusions
We have demonstrated before that KLHL12, a BTB-Kelch protein
which specifically interacts with the polymorphic repeats in the D4R
and promotes its ubiquitination also binds to β-arrestin 2 [35]. In thisstudy we characterized the interaction between KLHL12, β-arrestins
and D4R (see Fig. 13 for a schematic representation of all interactions
described in this study) and questioned its functional relevance.
Our data show that KLHL12 and Cullin3 interactwith bothβ-arrestin
1 and 2, but no influence of these interactions on D4R ubiquitination,
trafficking or p44/42 MAPK phosphorylation was observed. Taking
into account that D4R, KLHL12 and β-arrestin 2 can exist in one protein
complex, it is unlikely that these interactions do not play a role in regu-
lation of the D4R function. Therefore, in future research the possibility of
the cooperative action of KLHL12 and β-arrestins in the modulation of
other D4R signaling pathways should be taken into consideration.Acknowledgements
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